GlassScriptPhysician profile
Thomas M Reid
NPI 1053381194
$6,083.26
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,472 · 2020: $813 · 2021: $1,119 · 2022: $1,057 · 2023: $1,017 · 2024: $605.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,662.54 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $975.28 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $546.59 | 2019-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $536.21 | 2019-2024 | Ingrezza |
| Allergan, INC. | $533.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $341.25 | 2019-2024 | Spravato |
| Alkermes, INC. | $267.35 | 2021-2024 | Lybalvi |
| Vanda Pharmaceuticals INC. | $234.04 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $164.51 | 2019-2024 | Austedo Xr, Austedo |
| Axsome Therapeutics, INC. | $163.30 | 2022-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $156.30 | 2019-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.14 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $76.66 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $74.74 | 2022-2023 | Quviviq |
| Shire North American Group INC | $61.44 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $33.21 | 2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $27.73 | 2019-2021 | |
| Eisai INC. | $24.25 | 2020-2021 | |
| Almatica Pharma LLC | $16.26 | 2023 | Loreev Xr |
| Merck Sharp & Dohme LLC | $14.09 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.08 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.52 | 2022 | |
| Bausch Health US, LLC | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.